Estradiol

Selected oral and twice-weekly patch labels include moderate-to-severe menopausal vasomotor symptoms, vulvar / vaginal atrophy, hypoestrogenism from hypogonadism / castration / primary ovarian failure, and osteoporosis prevention in appropriately selected patients. For vaginal symptoms alone, consider a local vaginal product first; for osteoporosis prevention alone, consider non-estrogen options and individual fracture risk.

Vagifem treats atrophic vaginitis due to menopause. Estring treats moderate-to-severe vulvar / vaginal atrophy symptoms due to menopause. These selected low-dose products treat local symptoms and are not systemic vasomotor regimens. Estring is distinct from systemic-dose vaginal rings such as Femring, which is outside this profile.

The oral label also lists palliation of metastatic breast cancer in selected women / men and advanced androgen-dependent prostate cancer. These legacy labeled oncology uses need specialist assessment and are not routine menopausal therapy; no oncology regimen is supplied here. Gender-affirming therapy, injectable estradiol esters, gels / sprays, contraceptive combinations, and other vaginal products require separate review.

Vagifem:one 10 mcg insert using the supplied applicator daily for 2 weeks, then twice weekly (for example Tuesday / Friday). Estring:one 2 mg reservoir ring delivering approximately 7.5 mcg / day, positioned in the upper third of the vagina continuously for 90 days; remove and replace if ongoing therapy is appropriate. The 2 mg reservoir is not a daily dose. If expelled, rinse Estring in lukewarm water and reinsert; retaining it beyond 90 days risks loss of effect and local complications.

For systemic estrogen with an intact uterus, provide an adequate progestogen plan to reduce endometrial hyperplasia / cancer risk. After hysterectomy, progestogen is generally unnecessary, although residual endometriosis may warrant it. The Menopause Society states that recommended low-dose vaginal estrogen generally does not require progestogen; long-term trial data beyond 1 year are limited. Older Vagifem labeling contains a broader instruction to consider progestogen, so distinguish this from systemic dosing and individualize the plan.

Apply the selected patch immediately after opening its pouch to clean, dry lower abdomen / buttocks; never breasts. Press firmly about 10 seconds, rotate sites with at least 1 week before reuse, and avoid oily / irritated skin or waistlines. Replace twice weekly; if detached, reapply or replace at another site and keep the original schedule. The selected label uses continuous estrogen after hysterectomy and describes 3 weeks on / 1 week off with a uterus; coordinate the prescribed estrogen / progestogen regimen rather than changing schedules independently.

Selected products contraindicate unexplained genital bleeding, estrogen-dependent neoplasia, active / history of DVT or PE, specified arterial thromboembolic disease, hepatic disease, or hypersensitivity. Patch, Vagifem and current Estring also specify proteinC / proteinS / antithrombin deficiency or other thrombophilia. Oral labels specify active / recent arterial disease; patch / Vagifem / Estring include history. Oral and Vagifem / patch labels specify breast cancer / history (oral has a specialist metastatic-treatment exception). Current Estring no longer lists breast cancer history as a separate blanket contraindication; any cancer-survivor use requires individualized specialist discussion. Do not use for pregnancy.

FDA began requesting changes in November 2025 and approved an initial group in February 2026. The updated Estring label has no boxed warning. The selected oral, Sandoz patch and Vagifem public labels still contain earlier boxed language, including endometrial / cardiovascular and dementia-related warnings. FDA retains the endometrial-cancer box for systemic estrogen-alone products while removing other specified boxed risk statements as individual labels are updated. Check the actual dispensed product’s current label; neither a universal old class box nor universal box removal is accurate.

Systemic therapy can cause headache, breast tenderness, nausea, bloating, edema, bleeding / spotting and patch-site reactions. Vagifem trials reported back pain, diarrhea, vaginal itching and yeast infection; Estring may cause discharge, irritation or local injury. Serious risks are described above; their likelihood depends on route, regimen and patient factors, and frequencies from different product trials are not directly comparable.

Rifampin, carbamazepine, phenobarbital and St. John’s wort may lower estrogen exposure and alter effect or bleeding. Azoles, macrolides, ritonavir and grapefruit juice may increase exposure or adverse effects. Estring has no formal interaction studies; its label discusses potential systemic-estrogen CYP interactions, not a proven identical interaction magnitude for every route.

Estrogens increase thyroid-binding globulin and other binding proteins. Patients dependent on thyroid replacement may need a dose change; monitor thyroid function. Total thyroid or sex-hormone measures and some coagulation / lipid tests may shift, so interpret results in context rather than treating a binding-protein change as a new disease.

A progestogen’s own risks and contraindications must be reviewed when it is added for endometrial protection. Do not layer systemic and local regimens or substitute a systemic-dose vaginal ring without confirming the indication, total regimen, and product labeling.

The Menopause Society’s public 2022 statement favors the benefit–risk balance for bothersome symptoms in otherwise eligible women under 60 years or within 10 years of menopause; later initiation has greater absolute risks and needs individualized discussion. This is not a guarantee of safety or a universal stopping age. Periodically reassess symptoms, risks and preferences.

Estradiol menopausal products are not pregnancy treatments; oral labeling contraindicates known / suspected pregnancy, and Estring should not be used in pregnancy or lactation. Estrogens enter milk and can reduce milk production; other selected labels require clinical benefit-risk assessment. Patch / Vagifem / Estring are not indicated in children; oral pediatric safety / effectiveness is unestablished, and exposure before skeletal maturity can accelerate epiphyseal closure.

Hepatic impairment / disease is a contraindication in selected labels, not simply a reason to copy a reduced oral dose. Kidney / cardiac disease increases concern about fluid retention; no universal renal dosing algorithm is established, and Estring has no dedicated renal / hepatic PK studies. Any consideration of low-dose vaginal estrogen after breast cancer needs oncology coordination; do not override the selected product’s contraindications through a general guideline summary.

Estradiol is an endogenous estrogen that binds nuclear estrogen receptors in responsive tissues. It influences reproductive tissues and provides negative feedback on pituitary gonadotropins. Replacement can relieve estrogen-deficiency symptoms; local low-dose therapy primarily targets vaginal tissues.

Oral therapy undergoes hepatic first-pass metabolism; skin and vaginal absorption bypass initial first-pass delivery. Estradiol interconverts with estrone and estriol, undergoes conjugation and enterohepatic recycling, and is excreted in urine as parent / metabolite conjugates. Route and product design change systemic exposure; a patch mg / day, oral mg, and vaginal mcg dose cannot be converted by simple arithmetic.

Estring produces an initial absorption peak followed by relatively low steady systemic exposure while releasing about 7.5 mcg / day locally. Vagifem also has systemic absorption; neither is a zero-absorption product. Serum estradiol / FSH levels generally do not predict symptom response or establish safety for routine menopausal / local-atrophy management.

Review symptom response, adherence, uterine / progestogen plan, blood pressure, bleeding and breast findings at follow-up. Schedule breast screening according to age, risk and prior results; investigate unexplained persistent / recurrent bleeding. Monitor thyroid function when on replacement, triglycerides or calcium when clinically relevant, and fluid retention in cardiac / renal disease. Routine serum-hormone targeting is not established for these menopause regimens.

Seek urgent care for chest pain, shortness of breath, unilateral leg swelling, stroke symptoms, severe allergy, or sudden visual change. Report unexplained genital bleeding, breast changes, jaundice, severe headache or new pelvic / vaginal pain. Explain the selected patch / application or vaginal insertion instructions, replacement calendar, and current product warning status; do not self-substitute routes.

Excess estrogen may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness / fatigue or withdrawal bleeding. Obtain professional advice and stop the excessive exposure under clinical direction; treatment is supportive. An Estring kept longer than 90 days loses effective delivery rather than creating a standard overdose scenario.

Selected product

Sandoz twice-weekly estradiol transdermal system

Delivery rate

0.0375 mg / day

Reservoir / system area

0.585 mg estradiol ·3.75 cm² system

Example NDC

0781-7138-83 ·calendar pack of 8

Reviewed representative oral tablet:2 mg; current comparison oral label describes 0.5 / 1 / 2 mg micronized estradiol. Selected twice-weekly patches deliver 0.025, 0.0375, 0.05, 0.075, 0.1 mg / day. Vagifem:10 mcg insert in disposable applicator. Estring:2 mg reservoir releasing 7.5 mcg / day over 90 days. Weekly patches, creams, Imvexxy, Femring, gels / sprays and injectable esters are not interchangeable regimens and are outside this focused profile.

Selected representative oral tablet:20–25°C in tight, light-resistant child-resistant container. Patch:20–25°C, excursions 15–30°C; keep pouched until application, then fold used adhesive sides together and discard in a sturdy child-proof container, never flush. Vagifem:20–25°C, excursions 15–30°C; do not refrigerate. Estring:15–25°C in its sealed pouch. Keep all products out of children’s reach; follow the exact dispensed product’s instructions.